Cancer Research and Treatment

Case Report

Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach: Report of Three Cases: Ji Seon Oh, Jae-Lyun Lee, Mi-Jung Kim, Min-Hee Ryu, Heung Moon Chang, Tae Won Kim, Se Jin Jang, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Yoon-Koo Kang; Cancer Res Treat. 2006;38(3):178-183. Published online June 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.3.178

Neoadjuvant imatinib therapy used to treat locally advanced or metastatic gastrointestinal stromal tumors (GI ST) remains under active investigation. We studied three cases of locally advanced gastric GISTs treated with imatinib on a neoadjuvant basis, followed by a complete surgical resection. Three patients were diagnosed with locally advanced unresectable GIST of the stomach and were started on imatinib 400 mg/day. After the imatinib treatment, partial responses were achieved in all patients and the tumors were considered resectable. Surgical resection was done after 7, 11, and 8 months of imatinib therapy, respectively. In one case, a metastatic liver lesion was detected during the imatinib treatment using computed tomography scans, so the imatinib therapy was maintained for 11 months postoperatively. In the other two patients without distant metastasis, imatinib treatment was not restarted after surgery. Mutational analysis revealed a mutation in exon 11 of the c-kit gene in two patients, and wild-type c-kit and PDGFRA in one patient. During pathology review of all three cases, we noted several features common to imatinib treatment. There was no evidence of tumor recurrence in all three patients at respective follow-up visits of 22, 15, and 7 months. These results suggest that the neoadjuvant imatinib therapy is a potentially curative approach for selected patients with locally advanced GIST.

Citations

Citations to this article as recorded by

Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, Han-Kwang Yang, Akira Sawaki, Seiichi Hirota, Jie Zheng, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Toshirou Nishida, Lin Shen, Li-Tzong Chen, Yoon-Koo Kang
Cancer Research and Treatment.2016; 48(4): 1155. CrossRef
Correlation between Computed Tomography and Pathological Findings of Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate
Ki Choon Sim, Beom Jin Park, Na Yeon Han, Deuk Jae Sung, Min Ju Kim, Sung Bum Cho, Hyun Kwon Ha, Hyoung Rae Kim
Journal of the Korean Society of Radiology.2014; 71(5): 239. CrossRef
Diagnosis and Treatment of Gastrointestinal Stromal Tumor
Yoon-Koo Kang, Dong Hoe Koo
Korean Journal of Medicine.2013; 85(4): 341. CrossRef
Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
Yoon-Koo Kang, Hye Jin Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
Cancer Research and Treatment.2012; 44(2): 85. CrossRef
Efficacy of Imatinib Mesylate Neoadjuvant Treatment for a Locally Advanced Rectal Gastrointestinal Stromal Tumor
Kyu Jong Yoon, Nam Kyu Kim, Kang Young Lee, Byung Soh Min, Hyuk Hur, Jeonghyun Kang, Sarah Lee
Journal of the Korean Society of Coloproctology.2011; 27(3): 147. CrossRef
Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
Yoon-Koo Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Hye Jin Kang, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
Journal of Korean Medical Science.2010; 25(11): 1543. CrossRef
Clinical Practice Guideline for Adequate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
Yoon-Koo Kang
Journal of the Korean Medical Association.2007; 50(9): 830. CrossRef

11,356 View
86 Download
7 Crossref

Original Articles

Efficacy and Safety Study of Docetaxel as Salvage Chemotherapy in Metastatic Gastric Cancer Failing Fluoropyrimidine and Platinum Combination Chemotherapy: Jae-Lyun Lee, Min-Hee Ryu, Heung Moon Chang, Tae-Won Kim, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Jung Shin Lee, Yoon-Koo Kang; Cancer Res Treat. 2005;37(4):201-207. Published online August 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.4.201

Abstract PDF PubReader ePub

Purpose

Fluoropyrimidine (F) and platinum (P) combination chemotherapy has been widely used for the first line treatment of advanced gastric cancer (AGC). Docetaxel (D) has shown promising activity in this disease. The present study retrospectively investigated the efficacy of D monotherapy as salvage chemotherapy for AGC that is failing F and P combination chemotherapy.

Materials and Methods

A total of 34 patients, fitting the eligibility criteria, were included in this study. D was administered at a dose of 75 mg/m² IV every 3 weeks, with dexamethasone prophylaxis. Twenty-nine patients had measurable lesions. The median treatment-free interval was 38.5 days, and 91.2% of patients had progressed within 4 months of withdrawal of the first line chemotherapy.

Results

A total of 133 cycles of D were administered, with a median of 3.5 (1~8) cycles. From an intention-to-treat analysis, 6 patients achieved partial responses (PR), with a response rate of 20.7% (95% CI, 6.0~35.4). The duration of objective PRs in these six were 2.3+, 2.5+, 2.9, 3.0+, 6.2 and 6.8 months, respectively. Six patients showed a stable disease, but 15 showed progression. The median time to progression was 4.2 months (95% CI, 2.8~5.5), with a median overall survival since the start of D monotherapy of 8.4 months (95% CI, 5.5~11.3). Grade 3/4 neutropenia and febrile neutropenia occurred in 12.9% of patients and 3.1% of cycles. The incidence of grade 3 or worse non-hematological toxicities were as follows; peripheral sensory neuropathy 9.7%, asthenia 3.2% and allergic reaction 2.7%.

Conclusion

Docetaxel, 75 mg/m², is active in AGC as second-line chemotherapy after failure of prior exposure to the F and P combination chemotherapy, with a favorable toxicity profile.

Citations

Citations to this article as recorded by

Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer
Nao Tagawa, Erika Sugiyama, Masataka Tajima, Yasutsuna Sasaki, Seigo Nakamura, Hiromi Okuyama, Hisanori Shimizu, Vilasinee Hirunpanich Sato, Tadanori Sasaki, Hitoshi Sato
Cancer Chemotherapy and Pharmacology.2017; 80(4): 841. CrossRef
Efficacy and Safety of Trastuzumab-based Therapy in Combination with Different Chemotherapeutic Regimens in Advanced Esophagogastric Cancer – a Single Cancer-center Experience
Georg-Martin Haag, Leonidas Apostolidis, Dirk Jaeger
Tumori Journal.2014; 100(3): 237. CrossRef
Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
Nicolas Isambert, Gilles Freyer, Sylvie Zanetta, Benoît You, Pierre Fumoleau, Claire Falandry, Laure Favier, Sylvie Assadourian, Karen Soussan-Lazard, Samira Ziti-Ljajic, Veronique Trillet-Lenoir
Clinical Cancer Research.2012; 18(6): 1743. CrossRef
A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy
Jae-Lyun Lee, Min-Hee Ryu, Heung Moon Chang, Tae-Won Kim, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Minsun Kim, Young Joo Chun, Jung Shin Lee, Yoon-Koo Kang
Cancer Chemotherapy and Pharmacology.2008; 61(4): 631. CrossRef

9,943 View
54 Download
4 Crossref

Clinicopathological Analysis of Borrmann Type IV Gastric Cancer: Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim; Cancer Res Treat. 2005;37(2):87-91. Published online April 30, 2005; DOI: https://doi.org/10.4143/crt.2005.37.2.87

Abstract PDF PubReader ePub

Purpose

Borrmann type IV gastric cancer is often diagnosed only at an advanced stage, resulting in a prognosis poor. We performed a retrospective study of the clinical characteristics of Borrmann type IV gastric cancer and the prognostic factors affecting the survival rate in such patients.

Materials and Methods

Of 4,063 patients with all gastric cancers, 370 (9%) with Borrmann type IV gastric cancer were analyzed.

Results

The clinical characteristics of these patients included a higher incidence rate in young females, and higher rates of serosa exposure, metastasis to lymph nodes and early peritoneal dissemination. Of patients presenting with peritoneal seeding, those resected had a higher survival rate than those that were not. A univariate analysis showed that the prognostic factors affecting the survival rate following a curative resection were the location, occupied area and depth of the primary tumor, as well as the presence of lymph node metastasis and the tumor stage. A multivariate analysis indicated that the tumor location and stage were significant independent prognostic factors after a curative resection for Borrmann type IV gastric cancer.

Conclusion

In conclusion, the early diagnosis and treatment of patients with Borrmann type IV gastric cancer are essential for the better survival of these patients. Even in patients with advanced tumors, a noncurative palliative resection may improve the prognosis.

Citations

Citations to this article as recorded by

Borrmann Type IV Gastric Cancer: Computed Tomography Features and Corresponding Pathological Findings
Changfeng Ji, Yi Ma, Zhong Zheng, Song Liu, Zhengyang Zhou
Journal of Computer Assisted Tomography.2024; 48(2): 200. CrossRef
Clinicopathological and prognostic features of Borrmann type IV gastric cancer versus other Borrmann types: A unique role of signet ring cell carcinoma
Chengcai Liang, Yao Liang, Biyi Ou, Lei Yuan, Shuqiang Yuan
Saudi Journal of Gastroenterology.2023; 29(4): 240. CrossRef
PN3b as an independent risk factor for poor prognosis and peritoneal recurrence in Borrmann type IV gastric cancer: A retrospective cohort study
Yiran Chen, Yanyan Chen, Liping Wen, Laizhen Tou, Haiyong Wang, Lisong Teng
Frontiers in Surgery.2022;[Epub] CrossRef
Comparative Outcomes of Laparoscopic Gastrectomy and Open Gastrectomy for Scirrhous Gastric Cancer: A Multicenter Retrospective Cohort Study
Yusuke Fujita, Tatsuto Nishigori, Yoshio Kadokawa, Atsushi Itami, Masato Kondo, Hisahiro Hosogi, Seiichiro Kanaya, Hironori Kawada, Hiroaki Hata, Michihiro Yamamoto, Yousuke Kinjo, Eiji Tanaka, Dai Manaka, Seiji Satoh, Hiroshi Okabe, Shigeru Tsunoda, Masa
Annals of Surgery Open.2021; 2(2): e063. CrossRef
Are Borrmann’s Types of Advanced Gastric Cancer Distinct Clinicopathological and Molecular Entities? A Western Study
Cristina Díaz del Arco, Luis Ortega Medina, Lourdes Estrada Muñoz, Elena Molina Roldán, M. Ángeles Cerón Nieto, Soledad García Gómez de las Heras, M. Jesús Fernández Aceñero
Cancers.2021; 13(12): 3081. CrossRef
Borrmann Type IV Gastric Cancer: Focus on the Role of Gastrectomy
Chengcai Liang, Guoming Chen, Baiwei Zhao, Haibo Qiu, Wei Li, Xiaowei Sun, Zhiwei Zhou, Yingbo Chen
Journal of Gastrointestinal Surgery.2020; 24(5): 1026. CrossRef
Subtotal gastrectomy combined with chemotherapy: An effective therapy for patients with circumscribed Borrmann type IV gastric cancer
Hai-Bo Huang, Zi-Ming Gao, An-Qi Sun, Wei-Tian Liang, Kai Li
World Journal of Gastrointestinal Oncology.2020; 12(11): 1325. CrossRef
Role of Cancer-Associated Fibroblast in Gastric Cancer Progression and Resistance to Treatments
In-Hye Ham, Dagyeong Lee, Hoon Hur
Journal of Oncology.2019; 2019: 1. CrossRef
Endoscopic ultrasound‑guided fine‑needle aspiration biopsy for diagnosis of gastric linitis plastica with negative malignant endoscopy biopsies
Yingjian Ye, Shiyun Tan
Oncology Letters.2018;[Epub] CrossRef
Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer
Makiko Yasumoto, Etsuko Sakamoto, Sachiko Ogasawara, Taro Isobe, Junya Kizaki, Akiko Sumi, Hironori Kusano, Jun Akiba, Takuji Torimura, Yoshito Akagi, Hiraku Itadani, Tsutomu Kobayashi, Shinichi Hasako, Masafumi Kumazaki, Shinji Mizuarai, Shinji Oie, Hiro
Cancer Medicine.2017; 6(1): 235. CrossRef
Endoscopic ultrasound-guided cutting of holes and deep biopsy for diagnosis of gastric infiltrative tumors and gastrointestinal submucosal tumors using a novel vertical diathermic loop
Yu-Mei Liu, Xiu-Jiang Yang
World Journal of Gastroenterology.2017; 23(15): 2795. CrossRef
Clinicopathologic characteristics and prognosis of Borrmann type IV gastric cancer: a meta-analysis
Yifan Luo, Peng Gao, Yongxi Song, Jingxu Sun, Xuanzhang Huang, Junhua Zhao, Bin Ma, Yuan Li, Zhenning Wang
World Journal of Surgical Oncology.2016;[Epub] CrossRef
Borrmann type IV gastric cancer should be classified as pT4b disease
Jin-yu Huang, Zhen-ning Wang, Chun-yang Lu, Zhi-feng Miao, Zhi Zhu, Yong-xi Song, Hui-mian Xu, Ying-ying Xu
Journal of Surgical Research.2016; 203(2): 258. CrossRef
Limited significance of curative surgery in Borrmann type IV gastric cancer
Eun Young Kim, Han Mo Yoo, Kyo Young Song, Cho Hyun Park
Medical Oncology.2016;[Epub] CrossRef
An update on gastric cancer
Syed A. Ahmad, Brent T. Xia, Christina E. Bailey, Daniel E. Abbott, Beth A. Helmink, Meghan C. Daly, Ramya Thota, Cameron Schlegal, Leah K. Winer, S. Ameen Ahmad, Ali H. Al Humaidi, Alexander A Parikh
Current Problems in Surgery.2016; 53(10): 449. CrossRef
CA125 is a potential biomarker to predict surgically incurable gastric and cardia cancer
Taobo Luo, Wenhu Chen, Lifang Wang, Hongguang Zhao
Medicine.2016; 95(51): e5297. CrossRef
Undiagnosed Borrmann type IV gastric cancer despite repeated endoscopic biopsies and PET-CT examination: A case report
Fang-Qing Zhu, Hong-Jin Chu, Zhao-Hua Gong, Feng-Cai Du, Jian Chen, Li-Xin Jiang
Oncology Letters.2016; 12(2): 1485. CrossRef
Variable Endoscopic Findings and Clinicopathological Characteristics of Borrmann Type 4 Advanced Gastric Cancer
Ji Young Chang, Ki-Nam Shim, Chung Hyun Tae, A Reum Choe, Chang Mo Moon, Seong-Eun Kim, Hye-Kyung Jung, Sung-Ae Jung
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2015; 15(3): 166. CrossRef
Survival Benefit of Palliative Gastrectomy in Gastric Cancer Patients with Peritoneal Metastasis
Masanori Tokunaga, Masanori Terashima, Yutaka Tanizawa, Etsuro Bando, Taiichi Kawamura, Hirofumi Yasui, Narikazu Boku
World Journal of Surgery.2012; 36(11): 2637. CrossRef
Risk Stratification for Serosal Invasion Using Preoperative Predictors in Patients with Advanced Gastric Cancer
Sung-Sil Park, Jae-Seok Min, Kyu-Jae Lee, Sung-Ho Jin, Sunhoo Park, Ho-Yoon Bang, Hwang-Jong Yu, Jong-Inn Lee
Journal of Gastric Cancer.2012; 12(3): 149. CrossRef
An Insufficient Preoperative Diagnosis of Borrmann Type 4 Gastric Cancer in Spite of EMR
Jae Bong Ahn, Tae Kyung Ha, Hang Rak Lee, Sung Joon Kwon
Journal of Gastric Cancer.2011; 11(1): 59. CrossRef
Gastric carcinoma: when is palliative gastrectomy justified?
Hubert Scheidbach, Hans Lippert, Frank Meyer
Oncology Reviews.2010; 4(2): 127. CrossRef
Prognostic Factors in Gastric Cancer Patients with Peritoneal Carcinomatosis
Hyun Il Kim, Tae Kyung Ha, Sung Joon Kwon
Journal of Gastric Cancer.2010; 10(3): 126. CrossRef
Prognosis of pN3 Stage Gastric Cancer
Jung Ryun Ahn, Minkyu Jung, Chan Kim, Min Hee Hong, Hong Jae Chon, Hye Ryun Kim, Hei-Cheul Jeung, Woo Jin Hyung, Sung Sook Lee, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha
Cancer Research and Treatment.2009; 41(2): 73. CrossRef
Borrmann Type IV: An Independent Prognostic Factor for Survival in Gastric Cancer
Ji Yeong An, Tae Ho Kang, Min Gew Choi, Jae Hyung Noh, Tae Sung Sohn, Sung Kim
Journal of Gastrointestinal Surgery.2008; 12(8): 1364. CrossRef
Prognostic Factors for Advanced Gastric Cancer: Stage-stratified Analysis of Patients who Underwent Curative Resection
Joong-Min Park, Woo-Sang Ryu, Jong-Han Kim, Sung-Soo Park, Seung-Joo Kim, Chong-Suk Kim, Young-Jae Mok
Cancer Research and Treatment.2006; 38(1): 13. CrossRef

11,278 View
104 Download
26 Crossref

The Significance of Serum CA 19 - 9 Level in Gastric Adenocarcinoma: Yong Jin Kim, Byung Sik Kim, Jeong Hwan Yook, Sung Tae Oh, Byung Sun Suh, Wan Soo Kim, Yong Ho Kim, Kun Chun Park; J Korean Cancer Assoc. 2000;32(1):38-43.

Abstract PDF: PURPOSE
This study was designed to investigate the significance of preoperative serum CA 19-9 level as a prognostic factor and postoperative serum CA 19-9 level as an indicator for recurrence in gastric adenocarcinoma patients.
MATERIALS AND METHODS
328 patients, who received curative resection of stomach for gastric cancer from 1989 to 1996 and followed up successfully, were analyzed retrospec- tively. Median follow-up period was 24 months (range: 11-38 months). The cut off level of serum CA 19-9 was 37 U/ml. The relationships between preoperative serum CA 19-9 status and prognostic parameters, recurrence and survival rate were analyzed. Multivariate analysis using Cox proportional hazards regression analysis was performed to evaluate as an independent prognostic factor. The relationship between postoperative serum CA 19-9 level and recurrence was investigated.
RESULTS
Out of 328 cases, 29 cases (8.8%) showed elevated preoperative serum CA 19-9 level. The preoperative serum CA 19-9 level was correlated with the degree of depth of invasion and the status of lymph node metastasis (p<0.05). Patients with positive pre- operative serum CA 19-9 status showed higher incidence of recurrence (p<0.05) and poorer survival rate (p=0.00003) than patients with negative status. Preoperative serum CA 19-9 status (risk ratio: 3.4464, p=0.0039) revealed as an independent prognostic factor in multivariate analysis. Postoperative serum CA 19-9 status revealed as a useful predictor for recurrence in patients with positive preoperative serum CA 19-9 status.
CONCLUSION
Preoperative serum CA 19-9 determination in patients with gastric cancer was valuable for predicting tumor progression and prognosis. Preoperative serum CA 19-9 status may be helpful to predict recurrence earlier than other diagnostic tools, especially in the patients with positive preoperative serum CA 19-9 status.

3,070 View
17 Download

Diagnostic Value of Tumor Markers in Stomach Cancer: Jeong Hwan Yook, Byung Sik Kim, Yong Ho Kim, Byung Sun Suh, Wan Soo Kim, Sung Tae Oh, Kun Chun Park; J Korean Cancer Assoc. 1999;31(6):1094-1100.

Abstract PDF: PURPOSE
CEA, CA19-9, and CA72-4 are the most commonly used tumor markers in stomach cancer. This clinical study was performed to evaluate the diagnostic value of these tumor markers in stomach cancer patients.
MATERIALS AND METHODS
A retrospective analysis of 170 stomach cancer patients who had undergone curative gastrectomy between January 1991 and December 1996 at the Department of Surgery was performed. The preoperative and postoperative serum levels of these tumor markers were measured in 170 patients.
RESULTS
The preoperative positive cases were 28 cases (16%) in CEA, 15 (9%) in CA19-9, and 24 (14%) in CA72-4. The postoperative positive cases among 48 recurrences were 21 cases (44%) in CEA, 10 (21%) in CA19-9, and 10 (21%) in CA72-4. The combination of CEA with CA19-9 or CA72-4 had higher positivity rate (58%) than single tumor marker. The highest positivity rate was found in CEA at recurrences of anastomotic site, in CA19-9 at recurrences of lymph node, in CA72-4 at peritoneal seeding and distant metastasis. In multivariate analysis, these tumor markers were not independent prognostic factors.
CONCLUSION
CEA, CA19-9, and CA72-4 have proved unhelpful in initial diagnosis of stomach cancer because of their low positivity rate. And the combination of 3 tumor markers was the useful method for raising positivity rate in diagnosis of recurrences.

4,549 View
60 Download

In Vitro Chemosensitivity Test for the Evaluation of Efficiency of Hyperthermia in Gastrointestinal Cancer Cell Lines: Jeong Hwan Yook, Byeong Yul Ahn, Geum Hee Koo, Hun Seo, Choon Sik Jeong, Sung Tae Oh, Byung Sik Kim, Kun Chun Park, Jin Cheon Kim; J Korean Cancer Assoc. 1999;31(5):931-938.

Abstract PDF: PURPOSE
This study was designed to establish the experimental background of intra- peritoneal hyperthermo-chemotherapy in gastrointestinal cancer.
MATERIALS AND METHODS
We established stomach cancer cell lines; KATO-III, MKN45, AMC1 and colon cancer cell lines; AMC5, AMC6, CloneA, CCL188, C106, KM-12C. We performed chemosensitivity test by using MTT assay and calculated ICso of each chemotherapeutic agent. We confirmed antitumor effect of hyperthermia at 40C and 43C and antitumor synergistic effect with each chemotherapeutic agent at 40C and 43C.
RESULTS
The ICso was calculated in 7 (78%) of 9 cell lines for 5-FU, 6 (67%) for MMC, 5 (56%) for ADM, 1 (11%) for CDDP and VP-16. Antitumor effect of hyperthermia at 40C was not found, but, that at 43C was found except KATO-III and AMC6. In stomach cancer cell lines, antitumor synergistic effect of hyperthermia with anticancer drugs at 43C was found in VP-16 for MKN45 and KATO-III and in all of 5 drugs for AMC1. In colon cancer cell lines, this effect at 43C was found in all of 5 drugs for CCL188, in S-FU, CDDP, ADM for AMC5, in 5-FU, MMC, ADM, VP-16 for CloneA, KM-12C, and in 5-FU, CDDP, MMC, ADM for C106.
CONCLUSION
Hyperthermia itself had antitumor effect at 43C. Hyperthermo-chemotherapy had antitumor synergistic effect, especially at 43C.

2,571 View
21 Download

Effectiveness of Gastrectomy in Stage 4 Gastric Cancer with Hepatic Metastasis: Jeong Hwan Yook, Sung Joon Kwon, Byung Ki Kim, Byung Jae Kim, Sung Kim, Seung Moon Noh, Young Jae Mok, Kyung Kyu Park, Byung Ju Park, Cho Hyun Park, Ho Yoon Bang, Jae Moon Bae, Young Jin Song, Du Hyun Yang, Dae Hyun Yang, Sung Tae Oh, Hyo Yung Yun, Moo Son Lee, Jong Inn Lee, Yong Kwan Cho, Dong Wook Choi, Sang Uk Han; J Korean Cancer Assoc. 1999;31(3):441-447.

Abstract PDF: PURPOSE
The prognosis for patients with stage IV gastric cancer is very poor. However, recently, some studies have reported benefits from a gastric resection for metastatic gastric cancer. This clinical study was performed to evaluate the effectiveness of a noncurative gastrectomy in treating stage IV gastric cancer with hepatic metastasis.
MATERIALS AND METHODS
A retrospective analysis was performed on 98 gastric cancer patients who had undergone gastric resection, in spite of hepatic metastasis, between January 1990 and December 1996 at the Department of Surgery in 11 General Hospitals in Korea.
RESULTS
The average age was 58 years old, and the male-to-female ratio was 69: 29. The laboratory tests were unable to predict hepatic metastasis. In 54 cases, hepatic metastasis was not identified before the surgery. The most common location of gastric cancer was antrum (72 cases). The most common gross type was Bonmann type III (78 cases). The serosa-exposed cases were 80. The peritoneal seeding was combined in 17 cases. A total gastrectomy was performed in 18 cases and a distal gastrectomy in 80. Lymph-node dissection was performed in 23 Dl, and 51 D2 cases. Hepatic resection was performed in 36 cases, The frequent histologic types were moderately differentiated and poorly differentiated tubular adenocarcinoma. Postoperative adjuvant chemotherapy was done in 70 cases. The complication rate (7%) was low. The median survival time was 15 months, with mean survival time of 18 months. The 2-year and 3-year survival rates were 23%, and 7%, respectively. In the univariate analysis, good survival was closely related to limitation of hepatic metastasis to one lobe, a few metastases to both lobes, negativity of peritoneal seeding and lymph node dissection more than D2 (p<0.05), CONCLUSIONS: An aggressive gastric resection for stage IV gastric cancer with hepatic metastasis might be beneficial in lengthening the survival period. A prospective study is needed, especiaUy one with an exact evaluation and analysis of the quality of life between the gastrectomy and nonresection groups.

3,643 View
14 Download

Sugical treatment of stage IV gastric cancer: Sung Tae Oh, Kyung Rae Kim; J Korean Cancer Assoc. 1993;25(3):343-349.

Abstract PDF: No abstract available.

1,968 View
12 Download

Multivariate analysis of prognostic factors in stage II gastric cancer patients: Han Kwang Yang, Sung Tae Oh, Jin Pok Kim; J Korean Cancer Assoc. 1991;23(3):586-595.

Abstract PDF: No abstract available.

2,443 View
17 Download

Analysis of survival curves of gastric cancer patients according to TNM classification: Jin Pok Kim, Han Kwang Yang, Sung Tae Oh; J Korean Cancer Assoc. 1991;23(2):266-272.

Abstract PDF: No abstract available.

2,197 View
16 Download

First
Prev
Page of 1
Next
Last

Search